Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€4.39

€4.39

-1.390%
-0.062
-1.390%
€30.00
 
11:29 / Tradegate WKN: A2PKMZ / Symbol: NVAX / Name: Novavax / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
The full analysis of the stock Novavax Inc. is only available for our menbers.
Not a member yet? Sign up for free!

Financial data and news for Novavax

sharewise wants to provide you with the best news and tools for Novavax, so we directly link to the best financial data sources.

News

Is Novavax a Buy Now?: https://g.foolcdn.com/editorial/images/767610/gettyimages-1150572051.jpg
Is Novavax a Buy Now?

Novavax (NASDAQ: NVAX) has taken investors on a roller coaster ride over the past week or so. The stock soared after the company settled a dispute with a big customer, then sank as it reported

1 of the Biggest Risks Facing Novavax Has Now Been Resolved: Is Now the Time to Buy the Stock?: https://g.foolcdn.com/editorial/images/766670/scientist-conducting-an-experiment-in-a-lab.jpg
1 of the Biggest Risks Facing Novavax Has Now Been Resolved: Is Now the Time to Buy the Stock?

Since 2021, shares of Novavax (NASDAQ: NVAX) have absolutely crumbled, falling by a whopping 95%. Even with the price rally in recent days, the stock has still been a disastrous investment over the

Has Novavax Just Solved Its Biggest Problem?: https://g.foolcdn.com/editorial/images/766803/gettyimages-1295271909.jpg
Has Novavax Just Solved Its Biggest Problem?

Many investors have seen Novavax (NASDAQ: NVAX) as a promising recovery story ever since the biotech launched a plan to cut costs to better match the revenue opportunities ahead of it. Once one of

Where Will Novavax Be in 10 Years?: https://g.foolcdn.com/editorial/images/763753/nurse-in-ppe-loads-syringe.jpg
Where Will Novavax Be in 10 Years?

After a brutal three-year period that saw its shares collapse by 99%, any remaining longtime shareholders of Novavax (NASDAQ: NVAX) are doubtlessly eager for the biotech to finally step out of the

Better Recovery Story Buy: Novavax vs. Teladoc: https://g.foolcdn.com/editorial/images/763364/gettyimages-1199696916.jpg
Better Recovery Story Buy: Novavax vs. Teladoc

Everybody loves a good recovery story. You can get in on a promising company, with a potentially bright future ahead, but at a terrific price. And that means you could win big each time this player

Could Novavax Stock Help You Become a Millionaire?: https://g.foolcdn.com/editorial/images/763219/gettyimages-103919680.jpg
Could Novavax Stock Help You Become a Millionaire?

Novavax (NASDAQ: NVAX) stock may have made some millionaires back in 2020. It was the height of the coronavirus vaccine race, and investors were betting on this biotech company making it to the

1 Reason to Buy Novavax Stock, and 3 (Better) Reasons to Sell: https://g.foolcdn.com/editorial/images/762662/worker-holds-coronavirus-vaccine-syringe.jpg
1 Reason to Buy Novavax Stock, and 3 (Better) Reasons to Sell

Like many of the biotechs pursuing coronavirus vaccine development, Novavax (NASDAQ: NVAX) has seen better days. Its shares are down by 96% over the past three years, and the company's remaining

1 Reason to Buy Novavax Stock Hand Over Fist and 1 Reason to Sell: https://g.foolcdn.com/editorial/images/762839/gettyimages-1295986889.jpg
1 Reason to Buy Novavax Stock Hand Over Fist and 1 Reason to Sell

Novavax (NASDAQ: NVAX) shares have offered investors a roller coaster ride over the past few years. They soared more than 2,700% in early pandemic days as investors bet on the company's

Is It Too Late to Buy Novavax Stock?: https://g.foolcdn.com/editorial/images/762426/doctor-vaccinating-a-patient.jpg
Is It Too Late to Buy Novavax Stock?

A few years ago, biotech company Novavax (NASDAQ: NVAX) looked like a promising stock. It emerged as a leader in the development of a COVID-19 vaccine, which sent its share price through the roof.

Where Will Novavax Be in 5 Years?: https://g.foolcdn.com/editorial/images/762089/a-person-receiving-a-vaccine-from-a-nurse.jpg
Where Will Novavax Be in 5 Years?

There was a lot of promise around Novavax (NASDAQ: NVAX) and its COVID vaccine a few years ago. But with the company being late to the finish line and now generating limited revenue from the

Novavax Stock May Soar 379%, According to Wall Street. Is the Stock a Buy Right Now?: https://g.foolcdn.com/editorial/images/762140/gettyimages-1295271909.jpg
Novavax Stock May Soar 379%, According to Wall Street. Is the Stock a Buy Right Now?

Novavax (NASDAQ: NVAX) soared more than 2,700% early in the pandemic as investors bet on its ability to bring a coronavirus vaccine to market. The company followed through on that -- but not as

Is Novavax Stock a Buy Now?: https://g.foolcdn.com/editorial/images/756002/person-getting-vaccinated.jpg
Is Novavax Stock a Buy Now?

Biotech company Novavax (NASDAQ: NVAX) went from being relatively unknown just four years ago to becoming one of the U.S. COVID-19 vaccine market leaders. The company has faced many trials and

You Don't Have to Pick a Winner in Biotech. Here's Why.: https://g.foolcdn.com/editorial/images/755345/gettyimages-research-team-smiles-in-lab.jpg
You Don't Have to Pick a Winner in Biotech. Here's Why.

The biotech company that's able to deliver the next game-changing treatment might become tomorrow's winner -- and offer your portfolio a giant boost.

Problem is, it's not always easy to identify

Could a Short Squeeze Be Coming for These 3 Heavily Shorted Stocks?: https://g.foolcdn.com/editorial/images/754783/stock-traders-looking-at-a-chart.jpg
Could a Short Squeeze Be Coming for These 3 Heavily Shorted Stocks?

Wall Street traders have numerous (and often creative) strategies to speculate on stocks and their up and down price movements. There are times when the prices of stocks are influenced more by what

Where Will Novavax Be in 3 Years?: https://g.foolcdn.com/editorial/images/754676/gettyimages-1266812068.jpg
Where Will Novavax Be in 3 Years?

A lot can happen in just a few years, and Novavax (NASDAQ: NVAX) is the proof of that. Three years ago, the company was rushing toward the coronavirus vaccine finish line -- and the shares were

Down 75% From Its High, Has Novavax Stock Become Too Cheap to Pass Up?: https://g.foolcdn.com/editorial/images/752772/scientists-working-in-a-lab.jpg
Down 75% From Its High, Has Novavax Stock Become Too Cheap to Pass Up?

Novavax (NASDAQ: NVAX) is facing some significant headwinds. Its financials aren't in great shape, and its future remains questionable. Investors have been dumping the stock in droves, and it is no

Is Novavax Stock a Buy Now?: https://g.foolcdn.com/editorial/images/750474/nurse-vaccinating-elderly-patient.jpg
Is Novavax Stock a Buy Now?

If you had bought Novavax's (NASDAQ: NVAX) shares at the beginning of 2020, you'd be sitting on solid gains. The stock skyrocketed soon after the pandemic started as Novavax raced to develop a

The Fall Vaccination Season Is Here. Is Novavax a Buy?: https://g.foolcdn.com/editorial/images/750570/gettyimages-1295271909.jpg
The Fall Vaccination Season Is Here. Is Novavax a Buy?

Novavax (NASDAQ: NVAX) fell behind in the original coronavirus vaccine race as rivals Pfizer and Moderna brought their products to market. The biotech launched its vaccine a year-and-a-half later in

This Could be Novavax's Big Opportunity: https://g.foolcdn.com/editorial/images/749944/gettyimages-1266812068.jpg
This Could be Novavax's Big Opportunity

Early on in the pandemic, Moderna and Pfizer beat smaller rival Novavax (NASDAQ: NVAX) to market with their coronavirus vaccines by a year or more in some countries. This head start offered them the

Novavax’s dispute resolution and upcoming earnings call: https://www.marketbeat.com/logos/articles/med_20240222142457_novavaxs-dispute-resolution-and-upcoming-earnings.jpg
Novavax’s dispute resolution and upcoming earnings call

Novavax (NASDAQ: NVAX) is a biotechnology pioneer dedicated to developing innovative vaccines against serious infectious diseases. Their unique approach utilizes protein-based technology, an